Bizwit Research & Consulting LLP is a global provider of business intelligence & consulting services. We have a strong primary base of key industry leaders along with the chain of industry analysts to analyze the market trends and its future impact in order to estimates and forecast different business segments and markets. 

Global Healthcare Nanotechnology (Nanomedicine) Market to reach USD 482.99 billion by 2027.

Global Healthcare Nanotechnology (Nanomedicine) Market Size study, by Diseases (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases and Others), Application (Drug Delivery, Biomaterials, Active Implants and Others) and Regional Forecasts 2020-2027

Product Code: OIRPC_47331645
Publish Date: 7-01-2021
Page: 200

Global Healthcare Nanotechnology (Nanomedicine) Market is valued approximately USD 196.47 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 11.9 % over the forecast period 2020-2027. Healthcare Nanotechnology (Nanomedicine) is the product which is nano-formulations of the existing drugs or new drugs or nanomaterials. Nanomedicine helps in improving human health by providing solutions for various life-threatening diseases, like cancer, Parkinson’s disease, Alzheimer’s disease, diabetes, orthopedic diseases, and infections blood, lungs, and cardiovascular system. For instance: according to the Alzheimer’s Disease International, there were around 50 million people globally with dementia in 2020, which is expected to double every 20 years. According to the Globocan 2020, the global cancer burden increased to 19.3 million cases and 10 million cancer deaths in 2020. This will increase the demand for effective nanomedicines in the management of the diseases. Further, increasing investments in urgent care, increasing geriatric population and strategic development between hospitals and the manufacturers has led the adoption of Healthcare Nanotechnology (Nanomedicine) across the forecast period. The market has seen positive growth due to investments in new products by research & development. For Instance: in 2020, Medtronic PLC launched navigated titanium spinal implant, its new Adaptix Interbody System which is with the Titan nanoLOCK Surface Technology. In 2019, Nanobiotix, a clinical stage nanomedicine company had obtained the CE approval for its Hensify (NBTXR3), nanoparticles designed for injection directly into a tumor. However, stringent regulatory issues and high cost of nano-medicines compared to the traditional medicines along with low awareness among consumers in low income countries impedes the growth of the market over the forecast period of 2020-2027. Also, with the increasing prevalence of diseases, technological advancements for early disease diagnosis & preventive intervention the adoption & demand for Healthcare Nanotechnology (Nanomedicine) is likely to increase.

The regional analysis of global Healthcare Nanotechnology (Nanomedicine) market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the growing geriatric population and promptness & affordability of nano-medicines coupled with the well-established healthcare infrastructure along with the huge investments in research & development activities. For instance: according to the www.acc.org, in 2018, coronary heart disease was the leading cause of deaths attributable to cardiovascular disease in the United States with 43.8% of total CVD deaths. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rise in research grants, increasing venture capital investors from developing economies of this region and increasing international research collaborations along with the improving healthcare infrastructure would create lucrative growth prospects for the Healthcare Nanotechnology (Nanomedicine) market across Asia-Pacific region.

Major market player included in this report are:
Abbott Laboratories
CombiMatrix Corporation
GE Healthcare
Sigma-Tau Pharmaceuticals, Inc.
Johnson & Johnson
Mallinckrodt plc
Merck & Company, Inc.
Nanosphere, Inc.
Pfizer, Inc.
Celgene Corporation

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Diseases:
Cardiovascular Diseases
Oncological Diseases
Neurological Diseases
By Application:
Drug Delivery
Active Implants
By Region:
North America

Asia Pacific
South Korea
Latin America
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027

Target Audience of the Global Healthcare Nanotechnology (Nanomedicine) Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
1.2.1. Healthcare Nanotechnology (Nanomedicine) Market, by Region, 2018-2027 (USD Billion)
1.2.2. Healthcare Nanotechnology (Nanomedicine) Market, by Diseases, 2018-2027 (USD Billion)
1.2.3. Healthcare Nanotechnology (Nanomedicine) Market, by Application, 2018-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Healthcare Nanotechnology (Nanomedicine) Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Healthcare Nanotechnology (Nanomedicine) Market Dynamics
3.1. Healthcare Nanotechnology (Nanomedicine) Market Impact Analysis (2018-2027)
3.1.1. Market Drivers
3.1.2. Market Challenges
3.1.3. Market Opportunities
Chapter 4. Global Healthcare Nanotechnology (Nanomedicine) Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2017-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
Chapter 5. Global Healthcare Nanotechnology (Nanomedicine) Market, by Diseases
5.1. Market Snapshot
5.2. Global Healthcare Nanotechnology (Nanomedicine) Market by Diseases, Performance – Potential Analysis
5.3. Global Healthcare Nanotechnology (Nanomedicine) Market Estimates & Forecasts by Diseases 2017-2027 (USD Billion)
5.4. Healthcare Nanotechnology (Nanomedicine) Market, Sub Segment Analysis
5.4.1. Cardiovascular Diseases
5.4.2. Oncological Diseases
5.4.3. Neurological Diseases
5.4.4. Others
Chapter 6. Global Healthcare Nanotechnology (Nanomedicine) Market, by Application
6.1. Market Snapshot
6.2. Global Healthcare Nanotechnology (Nanomedicine) Market by Application, Performance – Potential Analysis
6.3. Global Healthcare Nanotechnology (Nanomedicine) Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
6.4. Healthcare Nanotechnology (Nanomedicine) Market, Sub Segment Analysis
6.4.1. Drug Delivery
6.4.2. Biomaterials
6.4.3. Active Implants
6.4.4. Others
Chapter 7. Global Healthcare Nanotechnology (Nanomedicine) Market, Regional Analysis
7.1. Healthcare Nanotechnology (Nanomedicine) Market, Regional Market Snapshot
7.2. North America Healthcare Nanotechnology (Nanomedicine) Market
7.2.1. U.S. Healthcare Nanotechnology (Nanomedicine) Market Diseases breakdown estimates & forecasts, 2017-2027 Application breakdown estimates & forecasts, 2017-2027
7.2.2. Canada Healthcare Nanotechnology (Nanomedicine) Market
7.3. Europe Healthcare Nanotechnology (Nanomedicine) Market Snapshot
7.3.1. U.K. Healthcare Nanotechnology (Nanomedicine) Market
7.3.2. Germany Healthcare Nanotechnology (Nanomedicine) Market
7.3.3. France Healthcare Nanotechnology (Nanomedicine) Market
7.3.4. Spain Healthcare Nanotechnology (Nanomedicine) Market
7.3.5. Italy Healthcare Nanotechnology (Nanomedicine) Market
7.3.6. Rest of Europe Healthcare Nanotechnology (Nanomedicine) Market
7.4. Asia-Pacific Healthcare Nanotechnology (Nanomedicine) Market Snapshot
7.4.1. China Healthcare Nanotechnology (Nanomedicine) Market
7.4.2. India Healthcare Nanotechnology (Nanomedicine) Market
7.4.3. Japan Healthcare Nanotechnology (Nanomedicine) Market
7.4.4. Australia Healthcare Nanotechnology (Nanomedicine) Market
7.4.5. South Korea Healthcare Nanotechnology (Nanomedicine) Market
7.4.6. Rest of Asia Pacific Healthcare Nanotechnology (Nanomedicine) Market
7.5. Latin America Healthcare Nanotechnology (Nanomedicine) Market Snapshot
7.5.1. Brazil Healthcare Nanotechnology (Nanomedicine) Market
7.5.2. Mexico Healthcare Nanotechnology (Nanomedicine) Market
7.6. Rest of The World Healthcare Nanotechnology (Nanomedicine) Market

Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Abbott Laboratories Key Information Overview Financial (Subject to Data Availability) Product Summary Recent Developments
8.2.2. CombiMatrix Corporation
8.2.3. GE Healthcare
8.2.4. Sigma-Tau Pharmaceuticals, Inc.
8.2.5. Johnson & Johnson
8.2.6. Mallinckrodt plc
8.2.7. Merck & Company, Inc.
8.2.8. Nanosphere, Inc.
8.2.9. Pfizer, Inc.
8.2.10. Celgene Corporation
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption

The study of the market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geographies to provide a better regional outlook. In the report, country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. Our analysts contact company executives, managers, key opinion leaders, and industry experts. This enables our analyst to derive the closest possible figures without any major deviations in the actual number.

Primary Research Sources:

  • Interview conducted with raw material suppliers & manufacturers.
  • Interview conducted with manufacturers, suppliers & distributors, researchers, & representatives of regulatory bodies.
  • Interview conducted with market players, industry experts, & independent consultants.
  • Secondary Research Sources:
  • Purchased Database: D&B Hoovers, Bloomberg, Inc., Business Information Industry Association, NAICS Association.
  • Internal Database: White papers, Certified Publications, Articles by Recognized Authors and Regulatory Bodies.
  • Government Databases: Food and Agriculture Organization (FAO), European Industrial Hemp Association (EIHA), World Health Organization (WHO), Food and Drug Administration (FDA), International Telecommunication Union (ITU), United States Department of Agriculture (USDA), International organization of Motor Vehicle Manufacturers (OICA).

Need Assistance

Contact Person -
Krishant Mennon
Call us @
+ 91 99931 15879
Email: sales@bizwitresearch.com


Why Choose Us?

Quality over Quantity

Backed by 60+ paid data sources our reports deliver crisp insights with no compromise quality.

Analyst Support

24x7 Chat Support plus
free analyst hours with every purchase

Flawless Methodology

Our 360-degree approach of market study, our research methods leave stones unturned.
Enquiry Now